|
|
Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-08-2554.
 Previous Article | Table of Contents | Next Article 
Blood, 15 July 2003, Vol. 102, No. 2, pp. 571-576
IMMUNOBIOLOGY
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
Susanne M. Schmidt,
Kerstin Schag,
Martin R. Müller,
Markus M. Weck,
Silke Appel,
Lothar Kanz,
Frank Grünebach, and
Peter Brossart
From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany
Survivin, a member of the inhibitor of apoptosis protein family, is expressed in almost all types of malignancies, making this protein a useful tool for the development of broadly applicable vaccination therapies. We used a recently identified HLA-A2 binding peptide and dendritic cells (DCs) from healthy donors to induce survivin-specific cytotoxic T lymphocytes (CTLs) in vitro. These T cells efficiently lysed target cells pulsed with the cognate peptide. Furthermore, survivin-specific CTLs recognized HLA-A2–matched tumor cell lines and primary malignant cells from patients with leukemia in an antigen-specific and HLA-restricted manner as demonstrated with the use of cold target inhibition assays and blocking antibodies. To validate the immunogenicity of survivin we performed the experiments in an autologous setting and used monocyte-derived DCs as targets. Interestingly, we found that DCs up-regulate survivin expression on stimulation with tumor necrosis factor  (TNF-). However, these mature DCs were not recognized by survivin-specific CTLs, whereas they lysed autologous mature DCs pulsed with the antigenic peptide or transfected with whole tumor RNA purified from a survivin-expressing cell line. To further analyze the possible use of survivin-specific CTLs in cancer therapies, we induced survivin-specific CTLs using peripheral blood mononuclear cells (PBMNCs) and DCs from a patient with chronic lymphocytic leukemia (CLL). The in vitro–generated T cells efficiently recognized autologous malignant CLL cells, whereas they spared autologous-purified nonmalignant B cells or DCs. Our results demonstrate that survivin epitopes are presented on a broad variety of malignancies and can be applied in vaccination therapies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. A. Vella, M. Yu, S. R. Fuhrmann, M. El-Amine, D. E. Epperson, and O. J. Finn
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer
PNAS,
August 18, 2009;
106(33):
14010 - 14015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nishida, M. Hudecek, A. Kostic, M. Bleakley, E. H. Warren, D. Maloney, R. Storb, and S. R. Riddell
Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
July 15, 2009;
15(14):
4759 - 4768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Greiner, L. Bullinger, B.-a. Guinn, H. Dohner, and M. Schmitt
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells
Clin. Cancer Res.,
November 15, 2008;
14(22):
7161 - 7166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ansen, M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano
Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21
Clin. Cancer Res.,
October 1, 2008;
14(19):
6125 - 6136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yokoyama, F. Grunebach, S. M. Schmidt, A. Heine, M. Hantschel, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells
Clin. Cancer Res.,
September 1, 2008;
14(17):
5503 - 5511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere
Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients
J. Immunol.,
July 1, 2008;
181(1):
431 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al.
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Blood,
February 1, 2008;
111(3):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Andersen, I. M. Svane, J. C. Becker, and P. t. Straten
The Universal Character of the Tumor-Associated Antigen Survivin
Clin. Cancer Res.,
October 15, 2007;
13(20):
5991 - 5994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kater, M. H. J. van Oers, and T. J. Kipps
Cellular immune therapy for chronic lymphocytic leukemia
Blood,
October 15, 2007;
110(8):
2811 - 2818.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
Clin. Cancer Res.,
October 1, 2007;
13(19):
5675 - 5679.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pennati, M. Folini, and N. Zaffaroni
Targeting survivin in cancer therapy: fulfilled promises and open questions
Carcinogenesis,
June 1, 2007;
28(6):
1133 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Boss, F. Grunebach, K. Brauer, M. Hantschel, V. Mirakaj, T. Weinschenk, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen
Clin. Cancer Res.,
June 1, 2007;
13(11):
3347 - 3355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Weck, F. Grunebach, D. Werth, C. Sinzger, A. Bringmann, and P. Brossart
TLR ligands differentially affect uptake and presentation of cellular antigens
Blood,
May 1, 2007;
109(9):
3890 - 3894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res.,
February 1, 2007;
13(3):
1053 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Riddell
Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy
Hematology,
January 1, 2007;
2007(1):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Coughlin, M. D. Fleming, R. G. Carroll, B. R. Pawel, M. D. Hogarty, X. Shan, B. A. Vance, J. N. Cohen, S. Jairaj, E. M. Lord, et al.
Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma
J. Clin. Oncol.,
December 20, 2006;
24(36):
5725 - 5734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart
BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia
Cancer Res.,
June 1, 2006;
66(11):
5892 - 5900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Altieri
Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.
Mol. Cancer Ther.,
March 1, 2006;
5(3):
478 - 482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mayr, D. M. Kofler, H. Buning, D. Bund, M. Hallek, and C.-M. Wendtner
Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells
Blood,
November 1, 2005;
106(9):
3223 - 3226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Huang, T. Tatsumi, E. Pizzoferrato, N. Vujanovic, and W. J. Storkus
Nitric Oxide Sensitizes Tumor Cells to Dendritic Cell-Mediated Apoptosis, Uptake, and Cross-Presentation
Cancer Res.,
September 15, 2005;
65(18):
8461 - 8470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baratelli, K. Krysan, N. Heuze-Vourc'h, L. Zhu, B. Escuadro, S. Sharma, K. Reckamp, M. Dohadwala, and S. M. Dubinett
PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells
J. Leukoc. Biol.,
August 1, 2005;
78(2):
555 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Kienle, C. Korz, B. Hosch, A. Benner, D. Mertens, A. Habermann, A. Krober, U. Jager, P. Lichter, H. Dohner, et al.
Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes
J. Clin. Oncol.,
June 1, 2005;
23(16):
3780 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong
Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24
Clin. Cancer Res.,
May 1, 2005;
11(9):
3377 - 3384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Frankenberger, H. Pohla, E. Noessner, G. Willimsky, B. Papier, A. Pezzutto, J. Kopp, R. Oberneder, T. Blankenstein, and D. J. Schendel
Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs
Clin. Cancer Res.,
March 1, 2005;
11(5):
1733 - 1742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Idenoue, Y. Hirohashi, T. Torigoe, Y. Sato, Y. Tamura, H. Hariu, M. Yamamoto, T. Kurotaki, T. Tsuruma, H. Asanuma, et al.
A Potent Immunogenic General Cancer Vaccine That Targets Survivin, an Inhibitor of Apoptosis Proteins
Clin. Cancer Res.,
February 15, 2005;
11(4):
1474 - 1482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mayr, D. Bund, M. Schlee, A. Moosmann, D. M. Kofler, M. Hallek, and C.-M. Wendtner
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes
Blood,
February 15, 2005;
105(4):
1566 - 1573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Andersen, I. M. Svane, P. Kvistborg, O. J. Nielsen, E. Balslev, S. Reker, J. C. Becker, and P. t. Straten
Immunogenicity of Bcl-2 in patients with cancer
Blood,
January 15, 2005;
105(2):
728 - 734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Schag, S. M. Schmidt, M. R. Muller, T. Weinschenk, S. Appel, M. M. Weck, F. Grunebach, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes
Clin. Cancer Res.,
June 1, 2004;
10(11):
3658 - 3666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood,
March 1, 2004;
103(5):
1763 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Schmidt, K. Schag, M. R. Muller, T. Weinschenk, S. Appel, O. Schoor, M. M. Weck, F. Grunebach, L. Kanz, S. Stevanovic, et al.
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis
Cancer Res.,
February 1, 2004;
64(3):
1164 - 1170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich
Full-Length Dominant-Negative Survivin for Cancer Immunotherapy
Clin. Cancer Res.,
December 15, 2003;
9(17):
6523 - 6533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Maecker, D. H. Sherr, R. H. Vonderheide, M. S. von Bergwelt-Baildon, N. Hirano, K. S. Anderson, Z. Xia, M. O. Butler, K. W. Wucherpfennig, C. O'Hara, et al.
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
Blood,
November 1, 2003;
102(9):
3287 - 3294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
